State Street’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,230,980
| Closed | -$286M | – | 4296 |
|
|
2025
Q2 | $286M | Sell |
2,230,980
-453,137
| -17% | -$47.1M | 0.01% | 725 |
|
|
2025
Q1 | $238M | Buy |
2,684,117
+183,910
| +7% | +$17.9M | 0.01% | 797 |
|
|
2024
Q4 | $218M | Sell |
2,500,207
-265,495
| -10% | -$24.3M | 0.01% | 887 |
|
|
2024
Q3 | $256M | Buy |
2,765,702
+385,818
| +16% | +$38.3M | 0.01% | 779 |
|
|
2024
Q2 | $257M | Buy |
2,379,884
+187,182
| +9% | +$18.7M | 0.01% | 733 |
|
|
2024
Q1 | $208M | Sell |
2,192,702
-231,498
| -10% | -$19.9M | 0.01% | 853 |
|
|
2023
Q4 | $224M | Sell |
2,424,200
-201,427
| -8% | -$13.1M | 0.01% | 781 |
|
|
2023
Q3 | $132M | Buy |
2,625,627
+122,634
| +5% | +$6.55M | 0.01% | 1005 |
|
|
2023
Q2 | $158M | Sell |
2,502,993
-252,286
| -9% | -$13.7M | 0.01% | 928 |
|
|
2023
Q1 | $124M | Sell |
2,755,279
-79,642
| -3% | -$3.59M | 0.01% | 1048 |
|
|
2022
Q4 | $124M | Buy |
2,834,921
+615,123
| +28% | +$29.5M | 0.01% | 1038 |
|
|
2022
Q3 | $146M | Sell |
2,219,798
-496,744
| -18% | -$31.9M | 0.01% | 880 |
|
|
2022
Q2 | $137M | Buy |
2,716,542
+449,648
| +20% | +$26.3M | 0.01% | 964 |
|
|
2022
Q1 | $145M | Buy |
2,266,894
+535,424
| +31% | +$38.4M | 0.01% | 1050 |
|
|
2021
Q4 | $185M | Buy |
1,731,470
+43,086
| +3% | +$4.51M | 0.01% | 901 |
|
|
2021
Q3 | $174M | Buy |
1,688,384
+39,138
| +2% | +$3.64M | 0.01% | 919 |
|
|
2021
Q2 | $145M | Buy |
1,649,246
+131,741
| +9% | +$12.1M | 0.01% | 1040 |
|
|
2021
Q1 | $148M | Sell |
1,517,505
-113,522
| -7% | -$11.3M | 0.01% | 952 |
|
|
2020
Q4 | $183M | Sell |
1,631,027
-182,261
| -10% | -$19.2M | 0.01% | 780 |
|
|
2020
Q3 | $168M | Sell |
1,813,288
-68,558
| -4% | -$5.28M | 0.01% | 744 |
|
|
2020
Q2 | $147M | Sell |
1,881,846
-77,995
| -4% | -$5.28M | 0.01% | 773 |
|
|
2020
Q1 | $115M | Buy |
1,959,841
+87,119
| +5% | +$5.61M | 0.01% | 789 |
|
|
2019
Q4 | $150M | Buy |
1,872,722
+41,536
| +2% | +$3.11M | 0.01% | 822 |
|
|
2019
Q3 | $135M | Buy |
1,831,186
+194,837
| +12% | +$16.8M | 0.01% | 836 |
|
|
2019
Q2 | $154M | Buy |
1,636,349
+300,700
| +23% | +$24.8M | 0.01% | 784 |
|
|
2019
Q1 | $107M | Sell |
1,335,649
-199,375
| -13% | -$14.7M | 0.01% | 965 |
|
|
2018
Q4 | $82.8M | Sell |
1,535,024
-150,176
| -9% | -$9.13M | 0.01% | 1017 |
|
|
2018
Q3 | $132M | Sell |
1,685,200
-164,083
| -9% | -$11.4M | 0.01% | 896 |
|
|
2018
Q2 | $117M | Buy |
1,849,283
+293,760
| +19% | +$23.4M | 0.01% | 930 |
|
|
2018
Q1 | $143M | Buy |
1,555,523
+53,117
| +4% | +$4.58M | 0.01% | 809 |
|
|
2017
Q4 | $113M | Buy |
1,502,406
+48,247
| +3% | +$3.39M | 0.01% | 955 |
|
|
2017
Q3 | $101M | Buy |
1,454,159
+54,124
| +4% | +$2.89M | 0.01% | 977 |
|
|
2017
Q2 | $70.9M | Buy |
1,400,035
+608,296
| +77% | +$25.8M | 0.01% | 1144 |
|
|
2017
Q1 | $31.7M | Buy |
791,739
+109,848
| +16% | +$3.93M | ﹤0.01% | 1612 |
|
|
2016
Q4 | $19.1M | Buy |
681,891
+358,089
| +111% | +$10.8M | ﹤0.01% | 1930 |
|
|
2016
Q3 | $9.62M | Sell |
323,802
-1,594
| -0.5% | -$39.6K | ﹤0.01% | 2209 |
|
|
2016
Q2 | $6.59M | Buy |
325,396
+191,138
| +142% | +$3.47M | ﹤0.01% | 2448 |
|
|
2016
Q1 | $2.43M | Buy |
134,258
+4,952
| +4% | +$85.9K | ﹤0.01% | 2925 |
|
|
2015
Q4 | $3.41M | Buy |
129,306
+13,130
| +11% | +$296K | ﹤0.01% | 2749 |
|
|
2015
Q3 | $2.48M | Buy |
116,176
+39,546
| +52% | +$1.09M | ﹤0.01% | 2906 |
|
|
2015
Q2 | $2.03M | Buy |
+76,630
| New | +$2.19M | ﹤0.01% | 3057 |
|
Other funds holding BPMC
IA
HNB
State Street's BPMC Position: Q3 2025 in Review
State Street sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 2,230,980 shares — an estimated $286M sold.
State Street first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $286M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- State Street reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- State Street sold 2,230,980 Blueprint Medicines shares in Q3 2025, an estimated $286M.
- State Street first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
- State Street's Blueprint Medicines position peaked at $286M in Q2 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on State Street's 13F filing for Q3 2025, filed 14 Nov 2025.